Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Cash flow is valuable, but it’s not everything - StockStory helps you identify the companies that truly put it to work. That said, here are three cash-producing companies that don’t make the cut and some better opportunities instead.
Ruger (RGR)
Trailing 12-Month Free Cash Flow Margin: 8.2%
Founded in 1949, Ruger (NYSE: RGR) is an American manufacturer of firearms for the commercial sporting market.
Why Do We Avoid RGR?
- Annual revenue declines of 3.8% over the last five years indicate problems with its market positioning
- Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
- Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results
Ruger is trading at $38.20 per share, or 20x forward P/E. Read our free research report to see why you should think twice about including RGR in your portfolio.
Integra LifeSciences (IART)
Trailing 12-Month Free Cash Flow Margin: 1.6%
Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ: IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments.
Why Should You Sell IART?
- Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth
- Incremental sales over the last five years were much less profitable as its earnings per share fell by 4.6% annually while its revenue grew
- 5× net-debt-to-EBITDA ratio shows it’s overleveraged and increases the probability of shareholder dilution if things turn unexpectedly
At $16.80 per share, Integra LifeSciences trades at 6.5x forward P/E. Check out our free in-depth research report to learn more about why IART doesn’t pass our bar.
Trupanion (TRUP)
Trailing 12-Month Free Cash Flow Margin: 5.4%
Born from a vision to help pet owners avoid economic euthanasia when faced with expensive veterinary bills, Trupanion (NASDAQ: TRUP) provides medical insurance for cats and dogs through data-driven, vertically-integrated products priced specifically for each pet's unique characteristics.
Why Are We Wary of TRUP?
- Capital trends were unexciting over the last five years as its 2.4% annual book value per share growth was below the typical insurance firm
- Estimated book value per share growth of 4.1% for the next 12 months implies profitability will slow from its two-year trend
- Negative return on equity shows management lost money while trying to expand the business
Trupanion’s stock price of $28.26 implies a valuation ratio of 2.8x forward P/B. If you’re considering TRUP for your portfolio, see our FREE research report to learn more.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
